A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).

Trial Profile

A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs RG 7800 (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions
  • Acronyms MOONFISH
  • Sponsors Roche
  • Most Recent Events

    • 23 Dec 2016 This trial has been completed in Spain (end date: 12 Dec 2016).
    • 20 Dec 2016 Status changed from suspended to discontinued due to unexpected toxicology, Dosing was suspended, the study was put on hold and eventually terminated..
    • 08 Dec 2015 Status changed from recruiting to suspended, according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top